The goal of this clinical trial is to learn if neurokinin-1/neurokinin-3 receptor antagonist elinzanetant improves blood vessel health in women with moderate to severe hot flashes. The main questions it aims to answer is does neurokinin-1/neurokinin-3 receptor antagonist elinzanetant improve blood vessel health?
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
80
elinzanetant 120 mg daily x 12 weeks
placebo daily x 12 weeks
Massachusetts General Hospital
Boston, Massachusetts, United States
RECRUITINGBrigham and Women's Hospital
Boston, Massachusetts, United States
RECRUITINGbrachial artery flow mediated dilation
Time frame: 12 weeks
concentration of inflammatory protein biomarkers
* General inflammatory markers: hsCRP, IL-8, TNF-ɑ/β * Leukocyte adhesion markers: MCP-1, ICAM-1 * Markers of vascular homeostasis: ANGPT1, VEGFA, HB-EGF
Time frame: 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.